Institution
Catholic University of the Sacred Heart
Education•Milan, Lombardia, Italy•
About: Catholic University of the Sacred Heart is a education organization based out in Milan, Lombardia, Italy. It is known for research contribution in the topics: Population & Health care. The organization has 13592 authors who have published 31048 publications receiving 853961 citations.
Topics: Population, Health care, Cancer, Myocardial infarction, Transplantation
Papers published on a yearly basis
Papers
More filters
••
Mario Negri Institute for Pharmacological Research1, Catholic University of the Sacred Heart2, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico3, Sapienza University of Rome4, Vita-Salute San Raffaele University5, University of Eastern Piedmont6, University of Messina7, Casa Sollievo della Sofferenza8, University of Padua9, Marche Polytechnic University10, University of Florence11
TL;DR: In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with an intended target of 45 to 50%.
Abstract: A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascular events, cardiovascular hospitalizations, incidence of cancer, progression to myelofibrosis, myelodysplasia or leukemic transformation, and hemorrhage. An intention-to-treat analysis was performed. Results After a median follow-up of 31 months, the primary end point was recorded in 5 of 182 patients in the low-hematocrit group (2.7%) and 18 of 183 patients in the highhematocrit group (9.8%) (hazard ratio in the high-hematocrit group, 3.91; 95% confidence interval [CI], 1.45 to 10.53; P = 0.007). The primary end point plus superficial-vein thrombosis occurred in 4.4% of patients in the low-hematocrit group, as compared with 10.9% in the high-hematocrit group (hazard ratio, 2.69; 95% CI, 1.19 to 6.12; P = 0.02). Progression to myelofibrosis, myelodysplasia or leukemic transformation, and bleeding were observed in 6, 2, and 2 patients, respectively, in the low-hematocrit group, as compared with 2, 1, and 5 patients, respectively, in the high-hematocrit group. There was no significant between-group difference in the rate of adverse events. Conclusions In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with a hematocrit target of 45 to 50%. (Funded by the Italian Medicines Agency and others; ClinicalTrials.gov number, NCT01645124, and EudraCT number, 2007–006694-91.)
611 citations
••
TL;DR: Next generation sequencing and copy number analysis provide insights into the complexity of the CLL coding genome, and reveal an association between NOTCH1 mutational activation and poor prognosis.
Abstract: The pathogenesis of chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is still largely unknown. The full spectrum of genetic lesions that are present in the CLL genome, and therefore the number and identity of dysregulated cellular pathways, have not been identified. By combining next-generation sequencing and copy number analysis, we show here that the typical CLL coding genome contains <20 clonally represented gene alterations/case, including predominantly nonsilent mutations, and fewer copy number aberrations. These analyses led to the discovery of several genes not previously known to be altered in CLL. Although most of these genes were affected at low frequency in an expanded CLL screening cohort, mutational activation of NOTCH1, observed in 8.3% of CLL at diagnosis, was detected at significantly higher frequency during disease progression toward Richter transformation (31.0%), as well as in chemorefractory CLL (20.8%). Consistent with the association of NOTCH1 mutations with clinically aggressive forms of the disease, NOTCH1 activation at CLL diagnosis emerged as an independent predictor of poor survival. These results provide initial data on the complexity of the CLL coding genome and identify a dysregulated pathway of diagnostic and therapeutic relevance.
609 citations
••
TL;DR: The endorsement of PRISMA resulted in increase of both quality of reporting and methodological quality of systematic reviews and meta-analyses published in journals in the field of gastroenterology and hepatology (GH).
Abstract: Introduction
PRISMA statement was published in 2009 in order to set standards in the reporting of systematic reviews and meta-analyses. Our aim was to evaluate the impact of PRISMA endorsement on the quality of reporting and methodological quality of systematic reviews and meta-analyses, published in journals in the field of gastroenterology and hepatology (GH).
Methods
Quality of reporting and methodological quality were evaluated by assessing the adherence of papers to PRISMA checklist and AMSTAR quality scale. After identifying the GH journals which endorsed PRISMA in instructions for authors (IA), we appraised: 15 papers published in 2012 explicitly mentioning PRISMA in the full text (Group A); 15 papers from the same journals published in 2012 not explicitly mentioning PRISMA in the full text (Group B); 30 papers published the year preceding PRISMA endorsement from the same journals as above (Group C); 30 papers published in 2012 on the 10 highest impact factor journals in GH which not endorsed PRISMA (Group D).
Results
PRISMA statement was referred in the IA in 9 out of 70 GH journals (12.9%). We found significant increase in overall adherence to PRISMA checklist (Group A, 90.1%; Group C, 83.1%; p = 0.003) and compliance to AMSTAR scale (Group A, 85.0%; Group C, 74.6%; p = 0.002), following the PRISMA endorsement from the nine GH journals. Explicit referencing of PRISMA in manuscript was not associated with increase in quality of reporting and methodological quality (Group A vs. B, p = 0.651, p = 0.900, respectively). Adherence to PRISMA checklist, and the compliance with AMSTAR were significantly higher in journals endorsing PRISMA compared to those not (Groups A+B vs. D; p = 0.003 and p = 0.016, respectively).
Conclusion
The endorsement of PRISMA resulted in increase of both quality of reporting and methodological quality. It is advised that an increasing number of medical journals include PRISMA in the instructions for authors.
605 citations
••
TL;DR: Perceived academic and self-regulatory efficacy concurrently and longitudinally deterred transgressiveness both directly and by fostering prosocialness and adherence to moral self-sanctions for harmful conduct.
Abstract: This longitudinal research examined a structural model of the self-regulatory mechanisms governing transgressive conduct Perceived academic and self-regulatory efficacy concurrently and longitudinally deterred transgressiveness both directly and by fostering prosocialness and adherence to moral self-sanctions for harmful conduct The impact of perceived social self-efficacy was mediated through prosocialness Moral disengagement and prosocialness affected transgressiveness through the mediating influence of irascible affectivity and hostile rumination Ruminative affectivity, in turn, both concurrently and longitudinally affected transgressiveness Moral disengagement also contributed independently to variance in transgressiveness over time This pattern of relations was obtained after controlling for prior transgressiveness The structural model was replicated across gender and provided a better fit to the data than did several alternative models
585 citations
••
Icahn School of Medicine at Mount Sinai1, University of Calgary2, Charles University in Prague3, Bezmialem Foundation University4, Medical University of Vienna5, Catholic University of the Sacred Heart6, University of Nice Sophia Antipolis7, University of Oxford8, Humanitas University9, University of California, San Diego10, Katholieke Universiteit Leuven11, University of California, Los Angeles12, AbbVie13, University of Amsterdam14
TL;DR: This trial aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients management with a clinical management algorithm.
575 citations
Authors
Showing all 13795 results
Name | H-index | Papers | Citations |
---|---|---|---|
Peter J. Barnes | 194 | 1530 | 166618 |
Cornelia M. van Duijn | 183 | 1030 | 146009 |
Dennis R. Burton | 164 | 683 | 90959 |
Paolo Boffetta | 148 | 1455 | 93876 |
Massimo Antonelli | 130 | 1272 | 79319 |
David B. Audretsch | 126 | 671 | 72456 |
Piero Anversa | 115 | 412 | 60220 |
Marco Pahor | 112 | 476 | 46549 |
David L. Paterson | 111 | 739 | 68485 |
Alfonso Caramazza | 108 | 451 | 39280 |
Anthony A. Amato | 105 | 911 | 57881 |
Stefano Pileri | 100 | 635 | 43369 |
Giovanni Gasbarrini | 98 | 894 | 36395 |
Giampaolo Merlini | 96 | 684 | 40324 |
Silvio Donato | 96 | 860 | 41166 |